D-0218-2025 Class II Ongoing

Recalled by Teva Pharmaceuticals USA, Inc — Parsippany, NJ

FDA drug recall D-0218-2025 was initiated by Teva Pharmaceuticals USA, Inc on Jan 10, 2025 and is designated Class II. Reason for recall: Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit The recall status is ongoing. Affected quantity: 34,636 cartons.

Recall details

Product Type
Drugs
Report Date
Feb 12, 2025
Initiation Date
Jan 10, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
34,636 cartons

Product description

Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL, Single Dose prefilled syringe, packaged as a) 1 syringe in 1 CARTON, NDC 63459-910-11, Blister NDC 63459-910-12; (b)10 syringes in 1 CARTON, NDC 63459-910-15, Blister NDC 63459-910-12; (c) 1 syringe in 1 CARTON, NDC 63459-910-17 without safety guard and blister, Rx Only, Manufactured by: UAB Teva Baltics, Vilnius, Lithuania. Distributed by Teva Pharmaceuticals USA, Inc. North Wales PA 19454. Product of Israel.

Reason for recall

Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit

Distribution pattern

Product was distributed nationwide.

Code information

Lot # (a) 135738, (b) 137149, (c) 137148, Exp. date 09/30/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0218-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0218-2025. Report a data issue: hello@regdatalab.com.